Baxter(US:BAX) Newsfile·2025-11-17 13:11Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple malfunctions, injuries, and deaths related to these defects but failed to take adequate remedial actions [3]. - The complaint states that Baxter's public statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses in Baxter International, Inc. stock during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].